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1607-551X/Copyright ª 2014, KaohsiuAbstract Expressions of human p16 and p27 were tested for correlations with clinicopatho-
logic features of urothelial carcinoma (UC). Tissue microarrays (TMA) constructed from
paraffin-embedded specimens from 78 patients with UC were analyzed by immunohistochem-
ical staining. In 49 of the 78 tumors (63%), high p16 expression was associated with absence of
tumor invasiveness and low-grade carcinoma (pZ 0.003 and pZ 0.046, respectively). The p27
expression was high in 33 of the 78 tumors (42%) and showed a significant negative association
with invasiveness, carcinoma grade, and tumor size (p Z 0.016, p Z 0.046, and p Z 0.014,
respectively). KaplaneMeier analysis indicated that patients with high p27 levels had longer
than average overall survival (pZ 0.021). This study demonstrates that p16 and p27 are prog-
nostic indicators of tumor stage and grade in UC and that they provide clinicians with the ancil-
lary information needed for selecting suitable therapeutic strategies.
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Urothelial carcinoma (UC), the most common histological
type of malignant urinary tumor, can arise anywhere in the
urothelial lining of the urinary tract, from the urethra to
the renal pelvis. Based on its morphology and invasiveness,
this malignancy can be classified as low grade or high grade,
and noninvasive or infiltrating, respectively [1]. In Taiwan,
an unusually high incidence of upper urinary tract UC hasy Elsevier Taiwan LLC. All rights reserved.
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question remaining to be answered is whether the biolog-
ical characteristics of UC differ by anatomical location [4].
Stage, lymph node metastasis, and grade are well-
documented conventional prognostic factors for UC, but
these factors are inadequate to successfully predict which
patients will experience recurrence and/or metastasis
[5,6].
Cell cycle progression is controlled by the complex in-
teractions of cyclins, cyclin-dependent kinases (CDKs), and
their inhibitors. The best prognostic markers for survival,
recurrence, and progression are those involved in the G1/S
phase transition, such as cyclin D1 and E, and cyclin-
dependent kinase inhibitors (CDKI), such as p27 and p16
[7,8]. Two families of CDKI, INK4 (p16, p15, p18, and p19)
and CIP/KIP (p21, p27, and p57), regulate cell proliferation
and are essential for preventing neoplastic transformation.
Most of these cell cycle proteins have been analyzed in
immunohistochemical (IHC) studies of various carcinomas.
The expressions of some cell cycle proteins reportedly
predict recurrence and disease progression in patients with
bladder UC [9e11].
At chromosome 9p21, a region that is often altered in
various tumor types [12e15], the p16 gene acts as a tumor
suppressor by negatively regulating the G1/S cell cycle.
Point mutation, promoter hypermethylation, and p16
deletion are common in various human malignancies
[16e23]. Mutation of p16 reportedly has a major role in
early carcinogenesis and progression of many tumors
[15,24e26]. Additionally, p27, a member of the CIP/KIP
family of proteins, regulates the CDKs and, as a tumor
suppressor, it is a major negative regulator of the G1eS cell
cycle. Reduced p27 protein expression may result in tumor
development and/or progression [27].
This study investigated the relevance of p16 and p27
immunoexpression and evaluated its prognostic value in
UC, particularly in terms of clinicopathologic parameters.
Materials and methods
Patients and follow-up
This study analyzed 78 UC specimens archived between 1995
and 2000 by the Department of Pathology, Kaohsiung Medical
University Hospital, Kaohsiung City, Taiwan. All 78 patients
had undergone nephrectomy, ureterectomy, ureteroscopic
tumor excision, or cystectomy with complete tumor resec-
tion. Histologic data collection included invasiveness and
tumor grade according to the latest World Health Organi-
zation (WHO) classification [1]. The analysis included 14
urinary bladder, 37 ureter, and 27 renal pelvis specimens
obtained from 27 males and 51 females with UC (age range,
21e83 years; median age, 68 years). Fifty-four tumors were
classified as invasive, and 24 were classified as noninvasive.
Eleven tumors were classified as low grade, and 67 were
classified as high grade. The duration of patient follow-up
was calculated as the number of months from the date of
the positive diagnostic surgical procedure to the date of the
most recent cystoscopy, the most recent visit, or death. Of
the 78 treated patients, 68 had survived until the median
follow-up period (59.2 months). When calculating disease-free survival, patients with any recurrence (local, regional,
or distant) or patients who had died from any cause were
classified as failures at the time of recurrence or death; all
other patients were surveyed at the last follow-up. When
calculating overall survival, UC-related deaths were counted
as failures at the time of death; all other patients were
surveyed at the last follow-up.
Tissue microarray
The tissue microarray (TMA) was constructed using
formalin-fixed paraffin-embedded UC tissue samples. All
original slides were classified by two pathologists (C.C.W.
and C.Y.C) according to WHO criteria [1]. Slides containing
the representative area of the tumor were circled with a
color pen. In each case, one core of the tumor (diameter,
2.0 mm) was carefully transferred with forceps from the
selected areas to the recipient metal paraffin block box.
Four-mm sections of the TMA block were cut and stained
with hematoxylin-eosin to verify that the cores adequately
represented diagnostic areas.
IHC staining
The IHC staining to detect p16 and p27 was performed by
the streptavidin-biotin method. Briefly, sections were
deparaffinized and autoclaved at 121C for 10 minutes in
0.1M of a pH 6.0 citrate buffer (for p16) or in 0.1M of a pH
9.0 Target Retrieval Solution (for p27). Endogenous perox-
idase in the section was blocked by incubation in 3%
hydrogen peroxide for 5 minutes at room temperature.
After washing with Tris buffer solution (TBS) and incubation
with goat serum for 1 hour, the sections were incubated
with primary antibodies p16 (Clone F12, 1:50 dilution;
Santa Cruz Biotechnology, Dallas, CA, USA) and p27 (Clone
F8, 1:50 dilution; Santa Cruz Biotechnology) at room tem-
perature for 30 minutes. Biotinylated second antibody and
peroxidase-conjugated streptavidin from the DAKO Uni-
versal LSAB kit (DAKO, Glostrup, Denmark) were applied for
20 minutes each. Finally, sections were incubated in 303-
diaminobenzidine (DAB) for 5 minutes, counterstained with
hematoxylin, and mounted on a slide. Negative controls
were obtained by replacing the primary antibody with
nonimmune serum. Known tonsil and breast carcinoma
cases positive for p16 and p27 were used as positive con-
trols. Strong staining of lymphocytes was also used as an
alternative internal control for p27.
Immunostaining evaluation
Immunostaining intensity was evaluated by light micro-
scopy as described elsewhere [11]. Protein expressions
were evaluated by two independent observers with no
knowledge of the clinicopathologic data. The immunohis-
tochemical results were evaluated using semiquantitative
analysis. The samples were stratified into the following
three groups according to percentage of positive cell
nuclei: 1e10%, 11e50%, and > 50%. After the first statisti-
cal analysis showed no significant difference between these
three predefined cutoff values,  10% was defined as
negative, and >10% was defined as positive. For p16, cells
Figure 1. Immunohistochemical staining for p16 and p27. Non-invasive low-grade UC showing strong nuclear and cytoplasmic
staining for p16 (A). Non-invasive low-grade UC showing strong nuclear staining for p27 (B) (A, B: original magnification, 200).
p16 and p27 in urothelial carcinoma 455with cytoplasmic staining but no nuclear staining were
considered negative [28,29].
Statistical analysis
Statistical analysis was performed by Chi-square test. Survival
curveswerecalculated by theKaplaneMeiermethod, and log-
rank tests were performed. All statistical analyses were per-
formed using the SPSS version 14 (SPSS Inc., Chicago, IL, USA).
A p value < 0.05 was considered statistically significant.
Results
The analysis of p16 expression showed a combination of
nuclear and cytoplasmic staining in several tumors, but only
cells with clear nuclear staining were considered positive.Table 1 The correlations between expression of p16 and p27 w
thelial carcinoma.
Factors p16 expression
Low (%) High (%)
Sex
Male 8 (27) 22 (73) 0
Female 21 (44) 27 (56)
Age (y)
< 68 15 (38) 24 (62) 0
 68 14 (36) 25 (64)
Tumor size (cm)
< 3 13 (35) 24 (65) 0
 3 16 (39) 25 (61)
Location
Urinary bladder 3 (21) 11 (79) 0
Kidney 17 (46) 20 (54)
Ureter 9 (33) 18 (67)
Tumor invasiveness
Present 26 (48) 28 (52) 0
Absent 3 (13) 21 (87)
Histologic grade
Low 1 (9) 10 (91) 0
High 28 (42) 39 (58)
* p < 0.05 was considered statistically significant.
a The p value was determined by Chiesquare test.
b The p value was determined by Fisher’s exact test.High and low p16 expressions were observed in 49 (63%) and
29 (37%) cases, respectively. For p27, high and low protein
expression was detected in 33 (42%) and 45 (58%) tumors,
respectively (Fig. 1). Table 1 shows the IHC expression of
p16 and p27 in relation to clinicopathologic variables. The
p16 expression levels showed significant negative correla-
tions with tumor invasiveness and grade ( p Z 0.003 and
p Z 0.046, respectively) whereas p27 expression showed
significant negative correlations with tumor invasiveness,
grade, and size 3.0 cm (p Z 0.016, p Z 0.046, and
p Z 0.014, respectively). Other parameters, including sex,
age, and tumor location, were unassociated with p16 and
p27 expression. In addition, significant correlation was
found between expression levels of p16 and p27
(p Z 0.043). When using the Kaplan-Meier method to test
actuarial disease-related survival according to overall sur-
vival and disease-free survival for correlations with p16 andith clinicopathologic characteristics in 78 patients with uro-
pa p27 expression pa
Low (%) High (%)
.129 13 (48) 14 (52) 0.214
32 (63) 19 (37)
.815 25 (64) 14 (36) 0.252
20 (51) 19 (49)
.723 16 (43) 21 (57) 0.014*
29 (71) 12 (29)
.237 5 (36) 9 (64) 0.167
24 (65) 13 (35)
16 (59) 11 (41)
.003* 36 (67) 18 (33) 0.016a,*
9 (38) 15 (62)
.046b,* 3 (27) 8 (73) 0.046b,*
42 (63) 25 (37)
456 C.-H. Yang et al.p27 expression, the overall survival curves showed statis-
tically significant differences between the groups with high
and low p27 expression (log-rank test, p Z 0.021) (Fig. 2).
The patients who expressed low-level p27 in UC were
associated with poor prognoses. However, p16 expression
was unrelated to overall survival (log-rank test, pZ 0.489).
Nuclear p16 and p27 expression also showed no significant
associations with disease-free survival (log-rank test,
p Z 0.661 and p Z 0.108, respectively).
Discussion
Studies of cell cycle markers of disease-free, overall, and
disease-specific survival in UC have obtained mixed results
[30,31]. Possible reasons include the heterogeneity of cases
evaluated in different studies [9]. Cell cycle progression is
controlled by a system of CDKs and CDKIs. Hence, reduced
CDKI production causes uncontrolled cell cycling. Low
expression of p16 or p27 is a known marker of adverse
prognosis in many human cancers, particularly cancer of
the pancreas, esophagus, and head and neck (p16 expres-
sion) and cancer of the bowel, breast, and prostate (p27
expression) [25,32,33]. Because the CDKIs p16 is a tumor
suppressor protein that binds to cyclin/cdk4 or cyclin/cdk6
complexes, it blocks their kinase activity and inhibits pro-
gression to the S phase of the cell cycle [25]. In human
cancers, p16 is known to be an early marker for malignant
transformation [34]. A polymerase chain reaction study of
heterozygosity also showed a correlation with p16 expres-
sion but not with clinical outcome [35]. Therefore, in
assessing the value of p16 as a prognostic marker, IHC may
be better than analyzing point mutations or methylations
[36]. The current study examined both nuclear and cyto-
plasmic p16 expression because an abnormal p16 accumu-
lation in the nucleus can reportedly result in its penetration
into the cytoplasmic region [37]. This study showed
increased p16 expression in noninvasive and low-grade UCs.Figure 2. Kaplan-Meier plots illustrating the association
between p27 expression and overall survival in 78 UC patients.Nevertheless, the correlation between p16 loss and tumor
recurrence in superficial UC remains controversial. Some
studies have shown that reduced p16 expression predicts
recurrence of UC [38e40], which is consistent with the
observation in the current study that p16 expression cor-
relates negatively with invasiveness and grade in UC and
that it probably correlates positively with prognosis.
The p27 in the Cip/Kip family regulates progression from
G1 into S phase by binding and inhibiting the cyclin E/CDK2
complex needed for entry into S phase [32,41,42]. In
combination with other cell cycle protein abnormalities,
loss of p27 has been associated with an aggressive tumor
course and an unfavorable prognosis in patients with
bladder carcinoma [43,44]. The current study revealed high
p27 expression in low-grade UC and low expression in
muscle-invasive UC, which is consistent with other studies
[43,45e47]. In patients with high p27 expression, tumors
tended to be smaller and in an earlier stage. Those with
high p27 staining had a better overall survival rate
compared to those with low staining, which suggests that
p27 inhibited their tumor proliferation and progression.
Low p27 levels are associated with poor survival in breast,
lung, prostate, and bladder cancer [48e51], which suggests
that p27 acts as a tumor suppressor gene in various human
tumors. In this study, however, p16 and p27 expressions
revealed no significant associations with anatomic location
of UC or with disease-free survival of UC. Therefore,
further studies are needed to test these associations in a
larger sample size or over a longer follow-up period.
In conclusion, the finding that p16 and p27 are nega-
tively associated with prognostic indicators (tumor stage
and grade) of UC provides clinicians with useful ancillary
data for selecting therapeutic strategies in UC.
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